Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti‐BCMA CAR T‐Cell Therapy: A Case Report

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Prolonged and refractory hematotoxicity is a severe complication of anti‐BCMA CAR‐T cell therapy, associated with substantial morbidity. When conventional supportive measures (transfusions and hematopoietic growth factors) fail, alternative strategies are urgently needed. We report the case of a 55‐year‐old man who developed persistent cytopenias after idecabtagene vicleucel. Reinfusion of cryopreserved autologous stem cells (stem cell boost), administered without conditioning chemotherapy, resulted in rapid and complete hematopoietic recovery after 14 days. This case highlights the potential of stem cell boost as a salvage approach for prolonged post‐CAR‐T hematotoxicity and underscores the need for prospective multicenter studies to standardize indications, timing, and procedures for this intervention.

This publication has 11 references indexed in Scilit: